Synagis injection: reconstitution no longer required

Synagis (palivizumab), AbbVie's respiratory syncytial virus (RSV) prophylactic for use in high-risk infants and children under two years, has been reformulated and is now available as a solution for injection.

Further information
View Synagis drug record
Summary of Product Characteristics
Manufacturer: AbbVie

The licensed indications, dosing, contraindications and warnings for use, and safety profile for the solution are identical to that of the lyophilised powder formulation which has now been discontinued.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases